The immune response to tumors as a tool toward immunotherapy - PubMed (original) (raw)

Review

The immune response to tumors as a tool toward immunotherapy

F Pandolfi et al. Clin Dev Immunol. 2011.

Abstract

Until recently cancer medical therapy was limited to chemotherapy that could not differentiate cancer cells from normal cells. More recently with the remarkable mushroom of immunology, newer tools became available, resulting in the novel possibility to attack cancer with the specificity of the immune system. Herein we will review some of the recent achievement of immunotherapy in such aggressive cancers as melanoma, prostatic cancer, colorectal carcinoma, and hematologic malignancies. Immunotherapy of tumors has developed several techniques: immune cell transfer, vaccines, immunobiological molecules such as monoclonal antibodies that improve the immune responses to tumors. This can be achieved by blocking pathways limiting the immune response, such as CTLA-4 or Tregs. Immunotherapy may also use cytokines especially proinflammatory cytokines to enhance the activity of cytotoxic T cells (CTLs) derived from tumor infiltrating lymphocytes (TILs). The role of newly discovered cytokines remains to be investigated. Alternatively, an other mechanism consists in enhancing the expression of TAAs on tumor cells. Finally, monoclonal antibodies may be used to target oncogenes.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Pandolfi F, Cianci R, Lolli S, et al. Strategies to overcome obstacles to successful immunotherapy of melanoma. International Journal of Immunopathology and Pharmacology. 2008;21(3):493–500. - PMC - PubMed
    1. Kurnick JT, Ramirez-Montagut T, Boyle LA, et al. A novel autocrine pathway of tumor escape from immune recognition: Melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage Melan-A/MART-1 antigen through down-modulation of its promoter. Journal of Immunology. 2001;167(3):1204–1211. - PubMed
    1. Aranda F, Llopiz D, Díaz-Valdés N, et al. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Research. 2011;71(9):3214–3224. - PubMed
    1. Banerjea A, Hands RE, Powar MP, Bustin SA, Dorudi S. Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Colorectal Disease. 2009;11(6):601–608. - PubMed
    1. Zappacosta R, Caraceni D, Ciccocioppo L, et al. Is HPV-DNA testing a useful tool in predicting low-grade squamous intraepithelial lesion outcome? A retrospective longitudinal study. International Journal of Immunopathology and Pharmacology. 2010;23(1):317–326. - PubMed

Publication types

MeSH terms

LinkOut - more resources